MIRA INFORM REPORT

 

 

Report Date :

28.11.2013

 

IDENTIFICATION DETAILS

 

Name :

ETHYPHARM S.A. 

 

 

Registered Office :

194 bureaux de la Colline Bat D, Saint-Cloud, F-92213

 

 

Country :

France

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

15.01.1978

 

 

Com. Reg. No.:

311999833

 

 

Legal Form :

Public Subsidiary

 

 

Line of Business :

Subject is discovers and develops drugs for treating pain, cancer, gastrointestinal, cardiovascular and central nervous system diseases.

 

 

No. of Employees :

579

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

France

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

ECONOMIC OVERVIEW

 

The French economy is diversified across all sectors. The government has partially or fully privatized many large companies, including Air France, France Telecom, Renault, and Thales. However, the government maintains a strong presence in some sectors, particularly power, public transport, and defense industries. With at least 79 million foreign tourists per year, France is the most visited country in the world and maintains the third largest income in the world from tourism. France's leaders remain committed to a capitalism in which they maintain social equity by means of laws, tax policies, and social spending that reduce income disparity and the impact of free markets on public health and welfare. France's real GDP contracted 2.6% in 2009, but recovered somewhat in 2010 and 2011, before stagnating in 2012. The unemployment rate increased from 7.4% in 2008 to 10.3% in 2012. Youth unemployment shot up to 24.2% during the third quarter of 2012 in metropolitan France. Lower-than-expected growth and high unemployment costs have strained France's public finances. The budget deficit rose sharply from 3.4% of GDP in 2008 to 7.5% of GDP in 2009 before improving to 4.8% of GDP in 2012, while France's public debt rose from 68% of GDP to 90% over the same period. Under President SARKOZY, Paris implemented some austerity measures to bring the budget deficit under the 3% euro-zone ceiling by 2013 and to highlight France's commitment to fiscal discipline at a time of intense financial market scrutiny of euro-zone debt. Socialist Party candidate Francois HOLLANDE won the May 2012 presidential election, after advocating pro-growth economic policies, the separation of banks' traditional deposit taking and lending activities from more speculative businesses, increasing the top corporate and personal tax rates, and hiring an additional 60,000 teachers during his five-year term. The government's attempt to introduce a 75% wealth tax on income over one million euros for two years was struck down by the French Constitutional Council in December 2012 because it applied to individuals rather than households. France ratified the EU fiscal stability treaty in October 2012 and HOLLANDE's government has maintained France's commitment to meeting the budget deficit target of 3% of GDP during 2013 even amid signs that economic growth will be lower than the government's forecast of 0.8%. Despite stagnant growth and fiscal challenges, France's borrowing costs declined during the second half of 2012 to euro-era lows.

 

Source : CIA

 


Company name & address


 

ETHYPHARM S.A. 

                                                                                                                                                                                                                                                                                                                                                                           

 

194 bureaux de la Colline Bat D

 

 

Saint-Cloud, F-92213

France

 

 

Tel:

+33 01 41 12 17 20

Fax:

+33 01 41 12 17 30

 

www.ethypharm-pharmaceutical.
com

 

Employees:

579

Company Type:

Public Subsidiary

Corporate Family:

67 Companies

Ultimate Parent:

Astorg Partners S.A.S.

 

 

Incorporation Date:

15-Jan-1978

Financials in:

               

 

 

Fiscal Year End:

31-Dec-2011

Reporting Currency:

Euro

Annual Sales:

198.0

Total Assets:

190.6

 

 

Business Description

 

 

Ethypharm S.A. (Ethypharm) is a drug discovery company. It discovers and develops drugs for treating pain, cancer, gastrointestinal, cardiovascular and central nervous system diseases. The company’s marketed products include nurofentabs, calpol, solupred, oxynormoro, skenan, antara, axorid, secnol, buprenorphine drugsol, and monicor. Currently, 20 more new drugs are under development. The company owns and operates three manufacturing sites, Chateauneuf-en-Thymerais and Grand-Quevilly in France; and Shanghai in China. It has partnership with around 139 pharmaceuticl companies, namely, Abbott, Actavis, Alkaloid, Archimedes, Biogaran, Bristol-Myers Squibb, Chiesi, gsk, Hi-Tech Pharmaceutical, Meda, Merz, mundi pharma, Ranbaxy, Sancoz, Stada, Sanofi, Takeda, and Ratiopharm among others. The company markets its products in 52 countries across worldwide. Ethypharm is headquartered in Saint Cloud, France.

 

 

Industry

 

 

Industry

Pharmaceutical Manufacturing

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

ISIC Rev 4:

2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE Rev 2:

2120 - Manufacture of pharmaceutical preparations

NAICS 2012:

325412 - Pharmaceutical Preparation Manufacturing

UK SIC 2007:

2120 - Manufacture of pharmaceutical preparations

US SIC 1987:

2834 - Pharmaceutical Preparations

 

 


Key Executives   

 

Name

Title

Hugues Lecat

Chairman-Management Board & CEO

Jean-Jacques Bancel

CFO

Bruno Delie

Director-Business Development

Jean Hugues Lecat

Secretary

Jean-Marie Largouet

EDP manager

 

      

News   

 

Title

Date

Drug Delivery Technologies: Commercial Prospects 2013-2023

PR Web (4482 Words)

29-Oct-2013

Pharmaceutical composition containing fenofibrate and method for the preparation thereof

U.S. Patents (127 Words)

28-Oct-2013

US Patent Issued to Ethypharm on Oct. 22 for "Pharmaceutical composition containing fenofibrate and method for the preparation thereof" (French,... 
U.S. Fed News (201 Words)

22-Oct-2013

Ethypharm Assigned Patent


Targeted News Service (163 Words)

11-Sep-2013

U.S. Patents Awarded to Inventors in Florida (Sept. 11)


Targeted News Service (1988 Words)

11-Sep-2013

U.S. Patents Awarded to Inventors in New Jersey (Sept. 11)


Targeted News Service (7431 Words)

11-Sep-2013

 

 

Registered No.(FRA): 311999833

 

1 - Profit & Loss Item Exchange Rate: USD 1 = EUR 0.7191895 


2 - Balance Sheet Item Exchange Rate: USD 1 = EUR 0.770327

 

 

Corporate Overview

 

Location
194 bureaux de la Colline Bat D
Saint-Cloud, F-92213
France

 

Tel:

+33 01 41 12 17 20

Fax:

+33 01 41 12 17 30

 

www.ethypharm-pharmaceutical.com

Sales EUR(mil):

142.4

Assets EUR(mil):

146.8

Employees:

579

Fiscal Year End:

31-Dec-2011

 

 

 

Industry:

Biotechnology and Drugs

Incorporation Date:

15-Jan-1978

Company Type:

Public Subsidiary

Quoted Status:

Not Quoted

Registered No.(FRA):

311999833

 

Chairman-Management Board & CEO:

Hugues Lecat

 

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

 

ISIC Rev 4 Codes:

2100

-

Manufacture of pharmaceuticals, medicinal chemical and botanical products

 

NACE Rev 2 Codes:

2120

-

Manufacture of pharmaceutical preparations

 

NAICS 2012 Codes:

325412

-

Pharmaceutical Preparation Manufacturing

 

US SIC 1987:

2834

-

Pharmaceutical Preparations

 

UK SIC 2007:

2120

-

Manufacture of pharmaceutical preparations

 

 

Business Description

 

Oral Drug Delivery Systems Developer & Mfr

 

 

More Business Descriptions

 

Ethypharm S.A. (Ethypharm) is a drug discovery company. It discovers and develops drugs for treating pain, cancer, gastrointestinal, cardiovascular and central nervous system diseases. The company’s marketed products include nurofentabs, calpol, solupred, oxynormoro, skenan, antara, axorid, secnol, buprenorphine drugsol, and monicor. Currently, 20 more new drugs are under development. The company owns and operates three manufacturing sites, Chateauneuf-en-Thymerais and Grand-Quevilly in France; and Shanghai in China. It has partnership with around 139 pharmaceuticl companies, namely, Abbott, Actavis, Alkaloid, Archimedes, Biogaran, Bristol-Myers Squibb, Chiesi, gsk, Hi-Tech Pharmaceutical, Meda, Merz, mundi pharma, Ranbaxy, Sancoz, Stada, Sanofi, Takeda, and Ratiopharm among others. The company markets its products in 52 countries across worldwide. Ethypharm is headquartered in Saint Cloud, France.

 

 


Financial Data

 

Financials in:

EUR(mil)

 

Revenue:

142.4

Assets:

146.8

Current Assets:

67.3

 

Total Liabilities:

146.8

 

Issued Capital:

1.3

 

Net Worth:

101.0

 

 

 

Date of Financial Data:

31-Dec-2011

 

1 Year Growth

2.5%

NA

 

 

Subsidiaries

 

Company

Percentage Owned

Country

Ethypharm Inc

 

Canada

Ethypharm K.K.

 

Japan

 

 

Key Corporate Relationships

 

Bank:

Banque Regionale De L Ouest, Natixis Banque Populaire, Societe Generale

 

 

 

 

 

 

Strategic Initiatives

 

Sales and Distribution

Feb 28, 2011Ethypharm Sells Indian Subsidiary To Athena PharmEthypharm, a French pharmaceutical company, sold its Indian operations to Athena Pharm in order to refocus its activities on Europe, the US, China and Japan; different markets where Ethypharm’s know-how and its competence in the development and registration sectors are renowned.Present in India since 1997, Ethypharm employed 80 people in production, formulation, development and marketing. Athena Pharm will respect all contracts, and previous technical and commercial commitments of Ethypharm former Indian subsidiary and continue to provide best in class and seamless service to its clients. Hugues Lecat, chairman and CEO of the management board of Ethypharm, said, "The sale of our Indian subsidiary is part of the Ethypharm’s strategy to continue its growth by focusing our resources on our most profitable markets.â€Feb 07, 2011Ethypharm Appoints Bruno Delie As Executive Vice President Of Business DevelopmentEthypharm, a French pharmaceutical company, has appointed Bruno Delie as executive vice president of business development. Delie is also a member of the management board and he reports to Hugues Lecat, chairman and CEO of the management board.Delie began his career in Germany and Europe, where he held various strategic positions within Parke Davis, Roquette and Prographarm Group. In 2000, he decided to join Ethypharm as business development director Europe, and became vice president sales and marketing in 2004. 

 

Copyright © 2013 LexisNexis. All Rights Reserved.

© 2013 Dun & Bradstreet, Inc. All rights reserved.

© 2013 OneSource Inc. All Rights Reserved.

© 2013 GlobalData. All Rights Reserved.

 

 

Corporate Family

 

Total Corporate Family Members: 67 

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

 

Astorg Partners S.A.S.

Parent

Paris

France

Investment Services

39.7

14

 

OGF SA

Subsidiary

Paris

France

Miscellaneous Manufacturing

719.0

5,767

 

Acquisition by Pamplona Capital Management LLP proposed/announced.See corporate structure news on Astorg Partners S.A.S. for details

Societe des Bois et Panneaux Industriels

Unit

Reyrieux

France

Wood Product Manufacturing

 

100

 

Lorganisation Funeraire

Subsidiary

Paris

France

Death Care Services

3.5

34

 

Groupement Funeraire Francilien - G2F

Subsidiary

Paris

France

Death Care Services

2.4

 

 

Pompes Funebres Generales - Roblot

Division

Paris

France

Death Care Services

 

 

 

Metalor Technologies International SA

Subsidiary

NeuchĂ¢tel

Switzerland

Metal Products Manufacturing

439.7

1,625

 

Metalor Technologies SA

Subsidiary

Neuchatel

Switzerland

Metal Products Manufacturing

 

400

 

Metalor Technologies - Marin

Branch

Marin

Switzerland

Metal Products Manufacturing

 

400

 

Metalor Finance SA

Subsidiary

Neuchatel

Switzerland

Banking

 

100

 

Metalor Technologies (France) SAS

Subsidiary

Courville sur Eure

France

Metal Products Manufacturing

488.0

389

 

Metalor Technologies (Suzhou) Ltd.

Subsidiary

Suzhou, Jiansu

China

Metal Products Manufacturing

 

200

 

Metalor Technologies Services México, S.A. De C.V.

Subsidiary

Naucalpan, Estado De Mexico

Mexico

Consulting Services

 

180

 

Metalor Technologies Operations México, S.A. De C.V.

Subsidiary

Naucalpan, Estado De Mexico

Mexico

Electrical Equipment and Appliances Manufacturing

 

148

 

Metalor Technologies (Hong Kong) Ltd.

Subsidiary

Kowloon

Hong Kong

Metal Products Manufacturing

 

60

 

Metalor Technologies (UK) Ltd

Subsidiary

Birmingham

United Kingdom

Metals and Minerals Wholesale

660.0

34

 

Metalor Technologies Singapore Pte. Ltd.

Subsidiary

Singapore

Singapore

Metal Products Manufacturing

233.9

21

 

Metalor Technologies (Italia) S.R.L.

Subsidiary

Milan

Italy

Metal Products Manufacturing

83.3

8

 

Metalor Technologies Iberica Sa

Subsidiary

Madrid

Spain

Metal Products Manufacturing

96.9

7

 

Metalor Technologies (Sweden) AB

Subsidiary

Boras

Sweden

Metal Products Manufacturing

36.0

4

 

Metalor Technologies (Japan) Corporation

Subsidiary

Minato-Ku, Tokyo

Japan

Miscellaneous Chemical Manufacturing

378.2

 

 

Metalor Technologies (Deutschland) GmbH

Subsidiary

Redwitz A.D.Rodach, Bayern

Germany

Electrical Equipment and Appliances Manufacturing

 

 

 

Metalor Technologies USA Corporation

Subsidiary

North Attleboro, MA

United States

Metal Products Manufacturing

 

 

 

Metalor Electrotechnics (U.S.A.) Corp.

Subsidiary

Export, PA

United States

Electrical Equipment and Appliances Manufacturing

6.6

200

 

Metalor Electrotechnics (Puerto Rico) LLC

Subsidiary

Luquillo, PR

United States

Electrical Equipment and Appliances Manufacturing

 

100

 

Metalor USA Refining Corporation

Subsidiary

North Attleboro, MA

United States

Metal Products Manufacturing

 

130

 

Metalor Technologies USA Corp

Branch

Export, PA

United States

Metal Products Manufacturing

36.5

199

 

Metalor Technologies USA Corp

Branch

Port Huron, MI

United States

Metal Products Manufacturing

7.3

7

 

Metalor Technologies USA Corp

Branch

Attleboro, MA

United States

Metal Products Manufacturing

5.4

7

 

Metalor USA Refining Corporation Succursal del Peru

Facility

Lima

Peru

Metal Products Manufacturing

 

4

 

Metalor Technologies USA Corp

Branch

Los Angeles, CA

United States

Nonclassifiable Establishments

 

3

 

Metalor Technologies USA Corp

Branch

Hialeah, FL

United States

Metal Products Manufacturing

0.6

1

 

Metalor Technologies (Hong Kong) Limited

Subsidiary

 

 

 

 

 

 

Metalor Technologies (Hong Kong) Limited Taiwan Branch

Subsidiary

Taipei City, Taipei

Taiwan

Miscellaneous Wholesale

 

12

 

Cerba

Subsidiary

St Ouen L Aumone

France

Physicians and Health Practitioners

 

749

 

Biolille Selarl

Subsidiary

Lille

France

Physicians and Health Practitioners

26.3

149

 

Ethypharm S.A.

Subsidiary

Saint-Cloud

France

Pharmaceutical Manufacturing

198.0

579

 

Linxens

Subsidiary

Guyancourt

France

Semiconductor and Other Electronic Component Manufacturing

129.3

375

 

FCI Microconnections Asia Pte Ltd

Subsidiary

Singapore

Singapore

Electrical Equipment and Appliances Manufacturing

77.7

134

 

SCT Telecom S.A.S.

Holding

La Plaine Saint-Denis

France

Wired Telecommunications Carriers

 

239

 

Onduline

Subsidiary

Levallois-Perret

France

Petroleum Product Manufacturing

 

34

 

Ondulin Stroitelnye Materialy Ooo

Subsidiary

Nizhni Novgorod

Russian Federation

Paper Product Manufacturing

61.5

9,168

 

Onduline France

Subsidiary

Yainville

France

Non-Metallic Mineral Product Manufacturing

70.2

105

 

Onduline Italia S.p.A.

Subsidiary

Lucca

Italy

Petroleum Product Manufacturing

29.9

75

 

Onduline Avrasya Insaat Malzemeleri Sanayi Ve Ticaret A S

Subsidiary

Istanbul (Anatolia)

Turkey

Wood Product Manufacturing

76.7

220

 

Onduclair

Subsidiary

Comines

France

Rubber and Plastic Product Manufacturing

25.7

72

 

Onduline Materiales De Construccion Sociedad Anonima

Subsidiary

Abanto Y Ciervana, Vizcaya

Spain

Petroleum Product Manufacturing

14.8

72

 

Onduline Materiais de Construcao, S.A.

Subsidiary

Porto

Portugal

Construction and Hardware Materials Wholesale

5.5

12

 

Onduline GmbH

Subsidiary

Wiesbaden, Hessen

Germany

Construction and Hardware Materials Wholesale

 

21

 

Onduline Material de Constructii S.r.l.

Subsidiary

Bucharest

Romania

Construction and Hardware Materials Wholesale

 

15

 

Onduline Materiale De Constructii Srl

Subsidiary

Bucuresti

Romania

Miscellaneous Wholesale

4.8

13

 

Onduline Building Products Ltd.

Subsidiary

London

United Kingdom

Miscellaneous Wholesale

8.3

11

 

Onduline S.M., s.r.o.

Subsidiary

Prague

Czech Republic

Construction and Hardware Materials Wholesale

 

10

 

Onduline - Construction Materials Ood

Subsidiary

Plovdiv

Bulgaria

Construction and Hardware Materials Wholesale

1.8

8

 

Onduline Belgique

Subsidiary

Petit-Rechain

Belgium

Petroleum Product Manufacturing

3.1

2

 

Ondulin Stroitelnye Materialy Zao

Subsidiary

Moscow

Russian Federation

Construction and Hardware Materials Wholesale

125.8

 

 

Onduline S.M., o.z.

Subsidiary

Bratislava

Slovakia

Construction and Hardware Materials Wholesale

 

 

 

Onduline Materialy Budowlane Sp. z o.o.

Subsidiary

Warsaw

Poland

Construction and Hardware Materials Wholesale

 

 

 

Photonis Holding

Subsidiary

Merignac

France

Banking

3.3

 

 

PHOTONIS France S.A.S.

Subsidiary

Brive-la-Gaillarde

France

Professional and Commercial Equipment Wholesale

87.8

589

 

Financiere Ofic

Holding

Levallois-Perret

France

Holding Companies

 

 

 

Financiere Du Jasmin

Subsidiary

 

 

 

 

 

 

Pino Elysees

Subsidiary

Paris

France

Hotels and Accommodation

56.2

374

 

Honorine

Subsidiary

 

 

 

 

 

 

STACI SAS

Subsidiary

Saint Ouen l'AumĂ´ne

France

Miscellaneous Professional Services

122.8

374

 

Publidispatch

Subsidiary

St Ouen L Aumone

France

Data Processing

59.9

 

 

Staci UK Ltd.

Subsidiary

London

United Kingdom

Storage and Warehousing

 

 

 

 

 

Competitors Report

 

CompanyName

Location

Employees

Ownership

Innate Pharma SA

Marseille, France

82

Public

 

 

Executives Report

 

 

Board of Directors

 

Name

Title

Function

 

Gilles Brisson

 

Supervisory Board of Directors

Chairman

 

Education:

HEC business school

 

Hugues Lecat

 

Chairman-Management Board & CEO

Chairman

 

Gerard Leduc

 

Founder & Vice Chairman-Supervisory Board

Vice-Chairman

 

Olivier Binet

 

Supervisory Board of Directors

Director/Board Member

 

Victor Casier

 

Supervisory Board of Directors

Director/Board Member

 

Christian Couturier

 

Supervisory Board of Directors

Director/Board Member

 

Benoit Durteste

 

Supervisory Board of Directors

Director/Board Member

 

Herve Guerin

 

Supervisory Board of Directors

Director/Board Member

 

Xavier Moreno

 

Supervisory Board of Directors

Director/Board Member

 

Philippe Reulet

 

Supervisory Board of Directors

Director/Board Member

 

Thierry Timsit

 

Supervisory Board of Directors

Director/Board Member

 

 

Executives

 

Name

Title

Function

 

Hugues Lecat

 

Chairman-Management Board & CEO

Chief Executive Officer

 

Jean Hugues Lecat

 

Secretary

Company Secretary

 

Jean-Jacques Bancel

 

CFO

Finance Executive

 

Daniela Kopczuk

 

Director-HR

Human Resources Executive

 

Jean-Marie Largouet

 

EDP manager

Information Executive

 

Pascal Oury

 

Head Pharmacist & Director-Scientific/Pharmaceutical Affairs

Research & Development Executive

 

 

Benedicte Berardo

 

Vice President Generic Products

Product Management Executive

 

Charlotte Haas

 

Vice President Specialty Products

Product Management Executive

 

Bruno Delie

 

Director-Business Development

Business Development Executive

 

Education:

HEC Business School, Master 
HEC Business School, MBA 

 

Roseline Joannesse

 

General Counsel

Legal Executive

 

Laurence Weber

 

Purchase manager

Purchasing Executive

 

 

Michel Couquelet

 

Director-Corporate Quality

Quality Executive

 

Cecile Paillous

 

Vice President Corporate Quality

Quality Executive

 

Regis Roussel

 

Director-Industry Affairs

Other

 

 

 

News



Drug Delivery Technologies: Commercial Prospects 2013-2023

PR Web (4482 Words)

29-Oct-2013

Pharmaceutical composition containing fenofibrate and method for the preparation thereof

U.S. Patents (127 Words)

28-Oct-2013

US Patent Issued to Ethypharm on Oct. 22 for "Pharmaceutical composition containing fenofibrate and method for the preparation thereof" (French,... 
U.S. Fed News (201 Words)

22-Oct-2013

Ethypharm Assigned Patent

Targeted News Service (163 Words)

11-Sep-2013

U.S. Patents Awarded to Inventors in Florida (Sept. 11)

Targeted News Service (1988 Words)

11-Sep-2013

U.S. Patents Awarded to Inventors in New Jersey (Sept. 11)

Targeted News Service (7431 Words)

11-Sep-2013

US Patent Issued to Ethypharm on Sept. 10 for "Pharmaceutical composition containing fenofibrate and method for the preparation thereof" (French,... 
U.S. Fed News (185 Words)

10-Sep-2013

Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion

U.S. Patents (96 Words)

12-Aug-2013

US Patent Issued to Ethypharm on Aug. 6 for "Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion"... 
U.S. Fed News (173 Words)

06-Aug-2013

CAV Chelsea Acquisition to combine with Pediapharm as QT

Canada StockWatch (2473 Words)

15-Jul-2013

Chelsea Acquisition Corporation Announces Proposed Qualifying Transaction

Marketwire (Canada) (2791 Words)

15-Jul-2013

 


Annual Profit & Loss

 

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate (Period Average)

0.778237

0.71919

0.755078

Consolidated

No

No

No

 

 

 

 

Total income

200.4

204.4

172.2

Net sales

187.5

198.0

154.8

Change in stock

-3.2

-0.5

-2.5

Unfinished work in progress

6.3

-6.4

4.4

Own work capitalised

4.8

6.7

7.8

Subsidies for operating costs

0.2

0.0

0.0

Supplementary operating income

1.6

3.8

5.2

Other operating income

0.0

2.2

0.0

Other external charges

47.0

51.2

47.4

Cost of goods sold

53.4

52.7

39.0

Taxes and social security costs

4.8

5.0

3.3

Social charges

16.8

16.4

14.6

Total payroll costs

34.8

36.0

34.4

Cost of stock depreciation and amortisation

2.0

1.4

1.6

Fixed asset depreciation and amortisation

12.8

13.7

13.3

Other operating costs

0.2

0.7

1.0

Total operating costs

168.5

176.6

152.0

Net operating income

31.8

27.9

20.2

Total financial income

23.6

7.9

16.4

Interest payable on loans

4.7

2.2

0.8

Other expenses

14.0

5.7

9.0

Total expenses

18.7

7.9

9.9

Profit before tax

36.7

27.9

26.8

Extraordinary income

3.0

5.1

11.4

Extraordinary expenses

8.0

7.5

15.7

Extraordinary result

-5.0

-2.3

-4.3

Total taxation

-2.3

-4.8

-1.3

Profit distributed to employees

2.1

1.6

1.4

Net profit

31.9

28.8

22.4

 

 

Annual Balance Sheet

 

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.7566

0.770327

0.745406

Consolidated

No

No

No

 

 

 

 

Issued capital

1.8

1.7

1.8

Share premium account

6.1

6.0

6.2

Legal reserves

1.1

0.9

0.8

Other reserves

1.3

-

0.2

Total reserves

27.9

27.4

28.3

Profits for the year

32.9

26.9

22.7

Profit brought forward from previous year(s)

86.2

68.2

61.1

Total stockholders equity

157.3

131.1

121.1

Provisions and allowances

5.6

4.9

8.2

Trade creditors

21.3

14.9

19.2

Advances received

1.2

0.0

0.4

Bank loans and overdrafts

6.7

10.2

15.0

Current bank debts

-

0.0

0.0

Other loans

2.3

7.1

6.4

Other liabilities

13.9

2.9

0.2

Debts on fixed assets

3.0

1.5

2.4

Income stated in advance

3.2

3.8

3.5

Taxation and social security

16.3

14.0

13.1

Total current liabilities

59.0

44.9

45.2

Total debts

68.0

54.4

60.3

Regularisation account

0.1

0.2

0.1

Total liabilities (including net worth)

230.9

190.6

189.7

Patents

3.1

2.4

2.9

Goodwill

38.3

37.6

38.8

Other intangibles

12.6

17.0

17.4

Land

0.1

0.1

0.1

Buildings

14.8

13.7

14.8

Other fixed assets

17.8

18.9

19.6

Long-term investments

1.4

1.4

1.4

Other financial assets

9.9

9.8

10.7

Total non-current assets

98.0

100.8

105.7

Prepayments

1.3

0.7

0.4

Net stocks and work in progress

26.1

16.8

21.9

Trade debtors

39.8

30.9

24.2

Other receivables

11.2

7.7

4.6

Prepaid expenses

0.9

0.1

0.8

Cash and liquid assets

37.2

12.3

16.6

Marketable securities

13.9

18.9

12.1

Total current assets

130.4

87.3

80.5

Prepaid expenses and deferred costs

2.6

2.4

3.5

Total assets

230.9

190.6

189.7

 

 


Annual Ratios

 

Financials in: USD (mil)

 

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

Period Length

12 Months

12 Months

12 Months

Filed Currency

EUR

EUR

EUR

Exchange Rate

0.7566

0.770327

0.745406

Consolidated

No

No

No

 

 

 

 

Current ratio

2.20

1.90

1.80

Quick ratio

1.80

1.60

1.30

Total liabilities to net worth

0.68%

0.76%

1.03%

Net worth to total assets

0.44%

0.38%

0.31%

Collection period

62.60

50.70

46.80

Stock turnover rate

7.40

11.00

7.20

Asset turnover

0.84%

0.97%

0.83%

Profit margin

0.20%

0.14%

0.17%

Return on assets

0.16%

0.14%

0.14%

Shareholders' return

0.38%

0.36%

0.46%

Sales per employee

1,472.49

1,531.49

1,260.99

Profit per employee

288.50

215.73

218.17

Average wage per employee

273.40

278.08

280.06

Net worth

157.3

131.1

121.1

Number of employees

650

610

608

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.36

UK Pound

1

Rs.101.11

Euro

1

Rs.84.68

 

 

INFORMATION DETAILS

 

Report Prepared by :

NNA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.